Sunshine Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Revenue	34.87	24.09	4.35	0.23	0.07	Upgrade
Revenue Growth (YoY)	44.75%	454.42%	1802.41%	219.88%	238.10%	Upgrade
Cost of Revenue	24.2	15.75	2.65	0.12	0.03	Upgrade
Gross Profit	10.67	8.34	1.7	0.11	0.05	Upgrade
Selling, General & Admin	14.94	10.83	9.48	1.87	0.61	Upgrade
Research & Development	0.93	1.86	0.81	0.67	0	Upgrade
Other Operating Expenses	0.39	0.29	0.06	-	-	Upgrade
Operating Expenses	16.48	13.12	10.37	2.55	0.62	Upgrade
Operating Income	-5.81	-4.79	-8.67	-2.44	-0.58	Upgrade
Interest Expense	-0.01	-0.14	-0.04	-0.33	-0.17	Upgrade
Interest & Investment Income	0.5	0.81	0.52	-	-	Upgrade
Currency Exchange Gain (Loss)	-0.04	-0	-0	0	0	Upgrade
Other Non Operating Income (Expenses)	-	-	-	-	0	Upgrade
EBT Excluding Unusual Items	-5.37	-4.11	-8.2	-2.77	-0.74	Upgrade
Impairment of Goodwill	-	-	-18.33	-	-	Upgrade
Other Unusual Items	-	-	0.01	-9.67	-2.05	Upgrade
Pretax Income	-5.37	-4.11	-26.51	-12.44	-2.78	Upgrade
Income Tax Expense	-0.23	0.4	0.23	-	-	Upgrade
Earnings From Continuing Operations	-5.13	-4.51	-26.74	-12.44	-2.78	Upgrade
Net Income	-5.13	-4.51	-26.74	-12.44	-2.78	Upgrade
Net Income to Common	-5.13	-4.51	-26.74	-12.44	-2.78	Upgrade
Shares Outstanding (Basic)	1	0	-	-	-	Upgrade
Shares Outstanding (Diluted)	1	0	-	-	-	Upgrade
Shares Change (YoY)	5371.73%	-	-	-	-	Upgrade
EPS (Basic)	-7.32	-351.35	-	-	-	Upgrade
EPS (Diluted)	-7.32	-351.35	-	-	-	Upgrade
Free Cash Flow	-14.19	-8.86	-5.44	-1.83	-0.66	Upgrade
Free Cash Flow Per Share	-20.22	-690.63	-	-	-	Upgrade
Gross Margin	30.59%	34.61%	39.04%	48.42%	63.80%	Upgrade
Operating Margin	-16.67%	-19.86%	-199.61%	-1068.24%	-807.83%	Upgrade
Profit Margin	-14.72%	-18.70%	-615.44%	-5444.41%	-3898.74%	Upgrade
Free Cash Flow Margin	-40.68%	-36.76%	-125.24%	-800.75%	-922.13%	Upgrade
EBITDA	-5.59	-4.64	-8.65	-2.43	-0.56	Upgrade
EBITDA Margin	-16.02%	-19.24%	-199.03%	-	-	Upgrade
D&A For EBITDA	0.22	0.15	0.03	0.01	0.01	Upgrade
EBIT	-5.81	-4.79	-8.67	-2.44	-0.58	Upgrade
EBIT Margin	-16.67%	-19.86%	-199.61%	-	-	Upgrade

Updated Nov 5, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q